UBS AM’s AbCellera Biologics ABCL Stock Holding History

UBS AM’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.9M	Sell	4,317,206 -3,258,270	-43%	-$15.9M	0.01%	748
2026 Q1	$26.4M	Sell	7,575,476 -301,153	-4%	-$1.08M	0.01%	789
2025 Q4	$26.9M	Buy	+7,876,629	New	+$35.2M	0.01%	757
2025 Q3	–	Sell	-8,471,619	Closed	-$29.1M	–	2273
2025 Q2	$29.1M	Sell	8,471,619 -7,199,444	-46%	-$17.9M	0.01%	898
2025 Q1	$34.9M	Buy	15,671,063 +11,171,063	+248%	+$32M	0.01%	764
2024 Q4	$13.2M	Sell	4,500,000 -90,103	-2%	-$251K	﹤0.01%	1123
2024 Q3	$11.9M	Sell	4,590,103 -8,523	-0.2%	-$23.6K	﹤0.01%	1147
2024 Q2	$13.6M	Buy	+4,598,626	New	+$17.4M	﹤0.01%	1010
2022 Q3	–	Sell	-31,998	Closed	-$341K	–	2738
2022 Q2	$341K	Buy	+31,998	New	+$271K	﹤0.01%	2434

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS AM's ABCL Position: Q2 2026 in Review

UBS AM reduced its AbCellera Biologics (ABCL) stake by 43% in Q2 2026, selling an estimated $15.9M and leaving 4,317,206 shares worth $33.9M. The position accounts for 0.01% of the portfolio, ranked #748.

UBS AM first reported a position in ABCL in Q2 2022 and has held it in 9 quarters since. The position peaked at $34.9M in Q1 2025. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

UBS AM held 4,317,206 shares of AbCellera Biologics worth $33.9M as of Q2 2026.
UBS AM sold 3,258,270 AbCellera Biologics shares in Q2 2026, an estimated $15.9M.
AbCellera Biologics made up 0.01% of UBS AM's portfolio in Q2 2026, its #748 holding.
UBS AM first reported a position in AbCellera Biologics in Q2 2022 and has held it in 9 quarters since.
UBS AM's AbCellera Biologics position peaked at $34.9M in Q1 2025.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.